Description
Picropodophyllotoxin (477-47-4) is a potent and selective inhibitor of insulin-like growth factor 1 receptor (IGF1R) which is non-competitive with ATP.1Displays no activity at IR, EGFR, FGFR or PDGFR. Inhibits IGF1R autophosphorylation IC50 ~ 1 nM.1Displays antiproliferative activity in numerous tumor cell lines, IC50 = 0.05 – 15 μM.2 Exhibits antiangiogenic activity.3Picropodophyllotoxin attenuates intimal hyperplasia after vascular injury.4Active in vivo.
Chemical Properties
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO. It comes from the rhizome of Dysosma versipellis (Hance.) M. Cheng, a plant of the Berberidaceae family.
Uses
Picropodophyllotoxin is an insulin-like growth factor-I (IGF-I) receptor kinase inhibitor
Uses
Insulin growth factor 1 receptor inhibitor, antineoplastic
Definition
ChEBI: An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.
General Description
Poly(2,5-bis(3-sulfonatopropoxy)-1,4-phenylene, disodium salt-
alt-1,4-phenylene) (PPP-OPSO3) is a water soluble conjugating polymer that can be used as a donor molecule. It has a poly(p-phenylene) skeleton with each repeating unit having two phenylene groups. It can be used for a variety of optoelectronic applications.
Biological Activity
Orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Inhibits IGF1R autophosphorylation (IC 50 ~ 1 nM), increases the fraction of cells in the G 2 /M phase and upregulates apoptosis. Exhibits antiproliferative effects in multiple cancer cell lines (IC 50 = 0.05 - 15 μ M), and has anticancer and antineovascularization activity in vivo .
Biochem/physiol Actions
Picropodophyllotoxin (PPP), an epimer of podophyllotoxin (PPT), has been reported to target insulin-like growth factor-I receptor (IGF-IR) and mediate anticancer functions. However, a study in 2007, has reported that PPP can induce G2-M cell cycle arrest even in IGF-IR deficient cells. Hence, the role of PPP in IGF-IR-mediated anticancer functions is debatable.
References
[1] ADA GIRNITA. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.[J]. Cancer research, 2004, 64 1: 236-242. DOI:
10.1158/0008-5472.can-03-2522[2] ADA GIRNITA. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.[J]. Clinical Cancer Research, 2006, 12 4: 1383-1391. DOI:
10.1158/1078-0432.ccr-05-1106[3] ELINE MENU. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival[J]. International Journal of Cancer, 2007, 121 8: 1857-1861. DOI:
10.1002/ijc.22845[4] ANTON RAZUVAEV MD Leonard G M Bimma Henderson MD, PHD Olle L M, PHD Magnus A M, et al. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling[J]. Journal of Vascular Surgery, 2007, 46 1: Pages 108-115. DOI:
10.1016/j.jvs.2007.02.066
